Stock Analysis

Medacta Group Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Source: Shutterstock

Medacta Group (VTX:MOVE) Full Year 2022 Results

Key Financial Results

  • Revenue: €437.1m (up 20% from FY 2021).
  • Net income: €46.2m (down 10% from FY 2021).
  • Profit margin: 11% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses.
  • EPS: €2.32 (down from €2.58 in FY 2021).
SWX:MOVE Earnings and Revenue Growth March 19th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medacta Group Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Switzerland.

Performance of the Swiss Medical Equipment industry.

The company's shares are up 1.8% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Medacta Group you should know about.

Valuation is complex, but we're helping make it simple.

Find out whether Medacta Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis